Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 15;58(3):426.
doi: 10.3390/medicina58030426.

Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks

Jung-Yoon Choe  1 , Seong-Kyu Kim  1
Affiliations

Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks

Jung-Yoon Choe et al. Medicina (Kaunas). .

Abstract

Background and Objective: Hematological indices have been considered reliable markers for assessment of disease activity in rheumatoid arthritis (RA). This study assessed whether hematological indices reflect changes in disease activity in patients with RA treated with Janus kinase (JAK) inhibitors. Materials and Methods: This study recruited 123 patients with RA who completed a regimen of JAK inhibitors, including baricitinib or tofacitinib, for 24 weeks, and 80 age- and sex-matched healthy control subjects. Hematological indices were systemic immune-inflammation index (SII), neutrophil-to-hemoglobin and lymphocyte (NHL) score, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Disease Activity Score 28 joints using erythrocyte sedimentation rate (DAS28-ESR) was evaluated as a measure of RA disease activity. Results: At baseline, patients with RA had a significantly higher SII, NHL score, NLR, and PLR than controls (p < 0.001 for all). SII, NHL score, NLR, and PLR at baseline were associated with DAS28-ESR (p < 0.05 for all). Changes in SII, NHL score, NLR, and PLR were associated with those in DAS28-ESR during treatment with JAK inhibitors. Such treatment markedly decreased SII, NHL score, and NLR values compared to those at baseline (p < 0.001 for all) but did not decrease PLR (p = 0.056). There were no differences in changes in SII, NHL score, NLR, and PLR between baricitinib and tofacitinib treatments. No hematological index showed predictive potential with respect to non-response to JAK inhibitor treatment. Conclusions: This study showed that hematological indices might be useful in monitoring changes in disease activity in patients with RA treated with JAK inhibitors.

Keywords: DAS28; JAK inhibitor; disease activity; hematological index; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

There are no financial and non-financial conflicts of interest for any of the authors regarding specific financial interests that are relevant to the work conducted or reported in this manuscript.

Figures

Figure 1
Figure 1
Study population flow chart. Abbreviation: JAK, Janus kinase.
Figure 2
Figure 2
Correlations between DAS28-ESR and hematological indexes at baseline. p-values were calculated by multivariate regression analysis after adjustment for age and gender. Abbreviations: DAS, disease activity score; ESR, erythrocyte sedimentation rate; SII, systemic immune-inflammation index; NHL, neutrophil-to-hemoglobin and lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
See this image and copyright information in PMC

References

    1. Aletaha D., Smolen J.S. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320:1360–1372. doi: 10.1001/jama.2018.13103. - DOI - PubMed
    1. Guo Q., Wang Y., Xu D., Nossent J., Pavlos N.J., Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. doi: 10.1038/s41413-018-0016-9. - DOI - PMC - PubMed
    1. Figus F.A., Piga M., Azzolin I., McConnell R., Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun. Rev. 2021;20:102776. doi: 10.1016/j.autrev.2021.102776. - DOI - PubMed
    1. Ruaro B., Casabella A., Paolino S., Pizzorni C., Ghio M., Seriolo C., Molfetta L., Odetti P., Smith V., Cutolo M. Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: Correlation with the Trabecular Bone Score (TBS) Clin. Rheumatol. 2018;37:3057–3062. doi: 10.1007/s10067-018-4322-9. - DOI - PubMed
    1. Anderson J.K., Zimmerman L., Caplan L., Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA) Arthritis Care Res. 2011;63((Suppl. 11)):S14–S36. - PubMed

Substances